RZLT Rezolute Inc
Company Analysis
Latest News
🔴 Rezolute Inc is trading 5.3% down today on post-rally consolidation and broader market weakness
Rezolute Inc is trading at $3.87 (5.3% down) as the stock undergoes consolidation following a sharp multi-day rally driven by positive Phase 3 ersodetug trial...
🔴 Rezolute Inc is trading 5.2% down today amid post-rally consolidation
Rezolute Inc is trading 5.2% down at $3.87 amid continued volatility following last week’s sharp rally and recent pullbacks. • The move appears to be part of...
🔴 Rezolute Inc is trading 5.3% down today on profit-taking after a multi-day rally tied to Phase 3 data
Rezolute Inc is trading at $4.27 (-5.32%) as shares pull back from a sharp multi-day run-up fueled by encouraging interim Phase 3 upLIFT data for ersodetug in...
🔴 Rezolute Inc is trading 5.1% down today, easing after a multi-day rally on positive Phase 3 data
Rezolute Inc is trading at $4.34 (5.1% down), easing after a multi-day rally driven by positive interim Phase 3 upLIFT data for ersodetug in tumor...
🟢 Rezolute Inc is trading 11% up today after positive interim Phase 3 ersodetug data
Rezolute Inc is trading at $4.43 (+10.75%) after the company reported positive interim data from its Phase 3 upLIFT study of ersodetug in tumor...
Rezolute Announces Positive Interim Data for Phase 3 Study of Ersodetug in Tumor Hyperinsulinism
Rezolute, Inc. provided a positive interim update on its ongoing open-label Phase 3 study (upLIFT) for its drug candidate, ersodetug, in treating tumor...
Rezolute's Drug Lets Tumor Patients Ditch IV Glucose — But Can a 16-Person Trial Justify a $430 Million Bet?
Shares of Rezolute surged as much as 12.3% to $4.49 in pre-market trading, capping a week-long rally of roughly 37% from $3.27, after the company posted...
🟢 Rezolute Inc is trading 12% up today after positive interim Phase 3 data for ersodetug
Rezolute Inc is trading 12% up at $4.49 in pre-market following positive interim Phase 3 upLIFT data for its drug ersodetug in tumor hyperinsulinism. • The...
Rezolute reports positive Phase 3 data, patients stop IV glucose treatment
Rezolute Inc. announced positive interim data from its Phase 3 upLIFT study of ersodetug. The drug treats tumor hyperinsulinism, a rare condition causing...